Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Afatinib for Patients with Acquired Resistance to EGFR TKIs? Perhaps in Combination with Erbitux, but Is It Tolerable?

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

With the recent approval of afatinib, now becoming commercially available as Gilotrif, there is the potential new strategy for patients with an EGFR mutation who develop acquired resistance to a different EGFR tyrosine kinase inhibitor (TKI) in an earlier line of therapy.  Afatinib was approved as a first line treatment for patients with an EGFR mutation, a setting in which I don't think it represents an especially appealing option, but does it perhaps represent an answer to the common question of how we should best treat patients who develop acquired resistance to another EGFR TKI?

I'd say that as a single agent, the answer is going to me no, except in a small minority of patients.  This question was directly studied in the LUX Lung-1 trial of afatinib vs. placebo in patients who had gone at least 12 weeks with stable disease or a response to Iressa (gefitinib) or Tarceva (erlotinib) previously, and it wasn't a resounding success for afatinib.  While afatinib was associated with a significant improvement in progression-free survival (PFS) of 3.3 vs. 1.1 months, afatinib conferred absolutely no improvement in overall survival (OS), and in fact median OS was more than a month longer in the recipients of placebo.  The better OS in the placebo arm was not a statistically significant difference, but it's not what you hope to see for a new targeted therapy.  Moreover, as discussed in my recent prior post about the potential role of afatinib, its side effect profile can be very challenging, typically worse than Iressa or Tarceva.

Afatinib has been available in an expanded access protocol for several months, and this has given me occasion to give it to several of my own EGFR mutation-positive patients with acquired resistance to Tarceva and those referred from other centers in the region as a potential therapy in this setting. In short, it has never been effective in any of the handful of patients I've treated, and all have experienced more toxicity than they had on Tarceva.  That's just a small sample, but it corroborates the larger experience with single agent afatinib. I know that there are rare patients who benefit, including at least one in the GRACE community, but I think it's fair to say that this is not a realistic expectation.

The combination of afatinib and cetuximab (Erbitux) has looked promising in a small study of 40 evaluable patients, and there are plans for it to be studied in a larger setting.  In the meantime, however, we know that skin side effects for this combination can be quite severe, and Erbitux isn't FDA approved for lung cancer, making it potentially challenging to have it covered by an insurer.  For these reasons of having it relatively unlikely to be covered without a potential/probably expense of thousands of dollars per month for patients and a real concern that it won't be a tolerable combination in a broad population, I don't think it becomes a viable treatment option off protocol without more research, even if it shows promise now.

That's one opinion, and we'll need to see how afatinib is actually integrated into practice once it becomes widely available.  We also don't yet know how it will be priced, which will certainly be a factor in its uptake.

Stay tuned as this story evolves.

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Hi Hopish hope,  Welcome to…
By JanineT GRACE … on
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on